GLP-1 for Dogs: The Drug Class, and Why Dogs Are Not First

GLP-1 (glucagon-like peptide-1) is a hormone the gut releases after eating. GLP-1 receptor agonists mimic parts of that signal and include the human drugs behind Ozempic and Wegovy. For dogs, the honest status is specific: no GLP-1 receptor agonist is FDA-approved for canine weight loss and no sponsor has announced a canine clinical trial. Akston has, however, named two preclinical candidates in its 2026 SEC S-1/A: AKS-724d and AKS-725d. Both were being tested in mice, and Akston reports no regulator engagement for them.

What Is Actually in Development for Dogs

The tracker now separates the real canine GLP-1 candidates from two better-known dog programmes that are not GLP-1s. That distinction is the difference between a genuine early pipeline signal and category confusion.

Slentrol matters for a reason beyond history. It is the proof that a canine weight-loss drug CAN clear the FDA, and the proof that clearing the FDA is not the same as lasting on the market.

Why the GLP-1 Trials Went to Cats First

This is the question the search data suggests dog owners are actually asking, and it has real answers rather than a shrug:

1. Dogs carry a breed-linked pancreatitis risk pattern that cats do not. Miniature Schnauzers, Yorkshire Terriers and Cocker Spaniels are predisposed, and GLP-1 medications carry pancreatitis warnings even on human labels. That combination raises the safety bar a canine programme has to clear before it starts.
2. Diet-led weight loss works better in dogs. Restriction-based weight loss in cats often triggers food aggression and resistance, because the species evolved as solitary hunters rather than gradual grazers. Dogs mostly have a portion problem, and a portion problem has a non-pharmaceutical fix. The unmet need is genuinely larger in cats.
3. Feline obesity prevalence is slightly higher. APOP's vet clinical survey puts US cat overweight and obesity prevalence at 61% against 59% for dogs.
4. Cats are a cleaner first indication for an implant. Okava's candidate is a subcutaneous implant releasing for up to six months, and a single narrow weight band makes dose-finding simpler than the roughly hundredfold body-weight range across dog breeds.

How the Cat Trials and Dog Candidates Relate

The two feline programmes are already in clinical development. Akston's two dog candidates are earlier analogs, so a feline readout may inform the platform without turning mouse testing into canine clinical evidence.

Neither company has announced a canine clinical trial start date. Okava/Vivani have disclosed an intention to develop for dogs without naming a compound; Akston has named AKS-724d and AKS-725d but places them in mouse testing. A programme is not a trial, and a trial is not an approval. Detail on each: MEOW-1 trial breakdown · Akston Biosciences · GLP-1 for cats.

Why You Cannot Get a Human GLP-1 for Your Dog

1. Species-specific dosing has never been established in dogs. GLP-1 receptor density and incretin response differ between species, so a dose scaled off a human label could be sub-therapeutic or unsafe in a dog of any size.
2. The pancreatitis interaction is unstudied in dogs. The predisposition above is documented; what a GLP-1 does on top of it is not. No veterinarian will sign that off without canine safety data.
3. FDA-CVM compounding guidance restricts it. FDA guidance for industry #256, made final April 14, 2022, limits the agency's enforcement discretion on compounding from bulk substances to cases where no other medically appropriate treatment option exists, and an overweight dog is not that when food therapy is the standard of care. FDA's draft GFI #256B of August 28, 2026 changes none of this: it is non-binding draft guidance about which facilities may compound, open for comment until November 27, 2026.

Gray-market vendors sell research-use peptide vials regardless. They come with no veterinary oversight, no purity guarantee, no canine dosing standard and no protocol if your dog reacts badly. That is the whole risk-reward calculation.

What to Do Instead, Starting Today

The useful news is that canine weight loss without medication has a far higher success rate than the human equivalent. Dogs do not have the willpower problem. They have the portion problem.

1. Confirm the dog is actually overweight on the 9-point Body Condition Score scale, because most owners are off by one to two points in either direction. Free dog weight checker.
2. Move to a vet-formulated weight management food, which cuts calorie density while holding protein so the dog still feels full. Weight loss dog food guide.
3. Portion against ideal weight, not current weight. Bag instructions assume an active adult dog already at its target.
4. Build exercise up gradually, because joint pain is common in obese dogs and a long walk on day one sets the plan back.
5. Re-weigh regularly. Roughly 1% to 2% of body weight per week is the range vets generally treat as safe. Slower is fine, faster risks muscle loss.

The wider picture on canine obesity, including the conditions that make a dog gain weight for reasons portions will not fix, is on our dog obesity page.